Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$10.23 - $12.94 $3,928 - $4,968
384 Added 0.78%
49,415 $519,000
Q2 2023

Aug 14, 2023

SELL
$5.92 - $12.72 $772,684 - $1.66 Million
-130,521 Reduced 72.69%
49,031 $565,000
Q1 2023

May 15, 2023

BUY
$6.74 - $9.44 $879,711 - $1.23 Million
130,521 Added 266.2%
179,552 $1.24 Million
Q3 2022

Nov 14, 2022

SELL
$3.31 - $13.06 $358,006 - $1.41 Million
-108,159 Reduced 68.81%
49,031 $490,000
Q2 2022

Aug 12, 2022

SELL
$6.0 - $9.37 $3.75 Million - $5.85 Million
-624,198 Reduced 79.88%
157,190 $1.37 Million
Q1 2022

May 13, 2022

BUY
$6.64 - $12.85 $291,110 - $563,369
43,842 Added 5.94%
781,388 $6.24 Million
Q4 2021

Feb 14, 2022

SELL
$10.81 - $14.38 $1.57 Million - $2.09 Million
-145,500 Reduced 16.48%
737,546 $9.91 Million
Q3 2021

Nov 15, 2021

BUY
$11.58 - $15.46 $7.62 Million - $10.2 Million
657,908 Added 292.22%
883,046 $11.5 Million
Q2 2021

Aug 16, 2021

SELL
$10.43 - $12.81 $312,900 - $384,300
-30,000 Reduced 11.76%
225,138 $2.61 Million
Q1 2021

May 17, 2021

SELL
$10.24 - $14.6 $3.92 Million - $5.59 Million
-382,956 Reduced 60.02%
255,138 $2.86 Million
Q3 2020

Nov 16, 2020

BUY
$8.73 - $15.15 $5.57 Million - $9.67 Million
638,094 New
638,094 $6.77 Million

Others Institutions Holding IMTX

About Immatics N.V.


  • Ticker IMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,227,000
  • Market Cap $343M
  • Description
  • Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...
More about IMTX
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.